Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 1,019 Shares

by · The Markets Daily

Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) VP Daniel Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $84.03, for a total value of $85,626.57. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,848,828.06. The trade was a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Edwards Lifesciences Trading Down 1.4%

NYSE EW traded down $1.18 during mid-day trading on Friday, hitting $83.06. The company’s stock had a trading volume of 2,855,741 shares, compared to its average volume of 4,440,979. The firm has a market capitalization of $48.20 billion, a P/E ratio of 35.80, a price-to-earnings-growth ratio of 3.77 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The stock’s fifty day simple moving average is $81.49 and its two-hundred day simple moving average is $78.95.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Econ Financial Services Corp acquired a new position in Edwards Lifesciences during the second quarter worth about $889,000. Randolph Co Inc bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at about $301,000. OMERS ADMINISTRATION Corp grew its stake in shares of Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Pacific Capital Partners Ltd bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $1,760,000. Finally, Arkadios Wealth Advisors bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $300,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on EW. Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, December 5th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. National Bankshares set a $92.00 target price on Edwards Lifesciences in a research note on Friday, October 31st. Barclays restated an “overweight” rating and issued a $103.00 price target (up previously from $99.00) on shares of Edwards Lifesciences in a research note on Monday. Finally, Evercore ISI increased their price objective on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.30.

Get Our Latest Research Report on EW

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Stories